NCT07248280
Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients
Registry fields
- Overall status
- COMPLETED
- Conditions
- Nausea and Vomiting, Postoperative, Prevention
- Study type
- INTERVENTIONAL
- Phase
- PHASE3
- Primary purpose
- PREVENTION
- Intervention type
- DRUG
- Interventions
- Aprepitant 40mg, Placebo
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM) (OTHER)
Cached at: 2026-08-28 23:27:21
Brief summary
Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis.
Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited.
This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.
Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited.
This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue